We have released exciting new coverage of the stem cell industry. Check it out and let me know what you think? [Read more…]
What is PRP? That is an important question, because it is becoming increasingly popular to consider regenerative approaches to repairing the human body.
How Does PRP Work?
PRP, short for platelet-rich plasma, is a convenient treatment option for many soft tissue injuries, because it only involves a blood draw from the arm. The blood is spun down in a centrifuge, separating out the platlet rich plasma (PRP) portion in which there are concentrated growth factors and cytokines. [Read more…]
OCTOBER 26-28, 2018 | HYATT REGENCY DOWNTOWN | AUSTIN, TEXAS
MedRebels welcomes practicing physicians to a cumulative 3-day educational symposium. Lectures on cellular-based and other regenerative therapies and their clinical applications for orthopaedics and pain management. During these lectures and workshops, physicians and leading scientists will present current research and clinical studies. They will address clinical pearls for implementing cellular therapy into a physician’s practice. Physicians will receive hands-on cadaveric training utilizing ultrasound-guidance and fluoroscopy. [Read more…]
Without a doubt, the cell therapy industry is coming of age. In addition to growing numbers of cell therapy clinical trials, numerous cell therapy products have been approved by regulatory agencies worldwide and 150+ cell therapy companies are competing within the global marketplace. These metrics are extremely important because they indicate that the market for cell therapy products is expanding.
However, one of the most telling trends within the industry is a growing interest among “big pharma” in cell therapy companies. [Read more…]
Abeona Therapeutics announced the U.S. FDA granted a Regenerative Medicine Advanced Therapy (RMAT) designation to ABO-102, the company’s AAV-mediated gene therapy for the treatment of Sanfilippo syndrome Type A (MPS IIIA), a rare autosomal-recessive lysosomal storage disease.
It was the 16th RMAT designation awarded by the FDA and a landmark achievement in that it makes Abeona the first company to achieve two RMAT designations.
Headquartered in Dallas, TX, Abeona (NASDAQ: ABEO) is a clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases. Abeona’s first RMAT designation was for its EB-101 gene therapy for Epidermolysis Bullosa in January 2018. [Read more…]